查看购物车
  • Traditional Chinese
  • English
封面
市场调查报告书
商品编码
1722815

2025 年至 2033 年抗高血脂药物市场规模、份额、趋势及预测（依药物类别、给药途径、配销通路及地区划分）

Antihyperlipidemic Drugs Market Size, Share, Trends and Forecast by Drug Class, Route of Administration, Distribution Channel, and Region, 2025-2033
出版日期: | 出版商: IMARC | 英文 149 Pages | 商品交期: 2-3个工作天内

价格

2024年全球抗高血脂药物市场规模价值131亿美元。展望未来， IMARC Group估计到2033年市场规模将达到186亿美元，2025-2033年期间的复合年增长率为3.9%。北美目前占据市场主导地位，到 2024 年将占据超过 32.7% 的显着市场。高血脂症和心血管疾病的高发性、人口老化、肥胖、久坐的生活方式和不健康的饮食习惯推动了北美市场的发展。强大的研发投入、先进的医疗保健基础设施、政府倡议、他汀类药物、PCSK9 抑制剂和新型降血脂药物的采用率不断提高，以及保险覆盖，进一步推动了抗高脂血症药物的市场份额。

抗高血脂药物有助于降低血清胆固醇和血液中的各种脂质的水平。它们可以与不同的药物一起服用，以控制高胆固醇并降低某些疾病的风险。目前，世界各地都有不同的类别，可以根据患者的胆固醇状况、潜在疾病和其他因素进行给药。一些常见的抗高血脂药物包括他汀类药物、抗高血脂组合、胆汁酸螯合剂、胆固醇吸收抑制剂、纤维酸衍生物和 PCSK9 抑制剂。

抗高血脂药物市场趋势：

久坐的生活方式、尼古丁成瘾和大量食用高脂肪食物导致高脂血症盛行率不断上升，这是催化抗高血脂药物需求的关键因素之一。此外，高血脂症会增加冠状动脉疾病（CAD）的风险，而冠状动脉疾病是全世界成年人最常见的死亡原因。因此，对这些药物的需求不断增加，以降低高密度脂蛋白（LDL）胆固醇和三酸甘油酯的过高水平，同时提高高密度脂蛋白（HDL）胆固醇的过低水平。除此之外，它们也用于治疗高胆固醇和各种脂质疾病的儿童。此外，儿科族群中遗传性和后天性脂质和脂蛋白代谢紊乱数量的激增，对抗高脂血症药物的需求产生了积极影响，以降低住院率和过早死亡率。此外，新型先进药物的批准也为市场创造了良好的前景。除此之外，世界各地的药物化学家正在设计、合成和评估这些药物的各种新分子，预计这将有助于市场的成长。

本报告回答的关键问题

  • 降血脂药市场有多大？降血脂药物市场未来前景如何？
  • 推动抗高血脂药物市场的关键因素有哪些？
  • 哪个地区占据抗高血脂药物最大的市占率？
  • 全球抗高血脂药物市场领先的公司有哪些？

目录

第一章：前言

第二章：范围与方法

  • 研究目标
  • 利害关係人
  • 资料来源
    • 主要来源
    • 次要来源
  • 市场评估
    • 自下而上的方法
    • 自上而下的方法
  • 预测方法

第三章：执行摘要

第四章：简介

  • 概述
  • 主要行业趋势

第五章：全球抗高血脂药物市场

  • 市场概览
  • 市场表现
  • COVID-19的影响
  • 市场预测

第六章：市场区隔：依药品类别

  • 他汀类药物
  • 胆汁酸螯合剂
  • 胆固醇吸收抑制剂
  • 纤维酸衍生物
  • PCSK9抑制剂
  • 组合
  • 其他的

第七章：市场区隔：依行政途径

  • 口服
  • 静脉

第八章：市场区隔：按配销通路

  • 医院药房
  • 零售店
  • 线上零售商

第九章：市场细分：依地区

  • 北美洲
    • 美国
    • 加拿大
  • 亚太
    • 中国
    • 日本
    • 印度
    • 韩国
    • 澳洲
    • 印尼
    • 其他的
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙
    • 俄罗斯
    • 其他的
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他的
  • 中东和非洲
    • 市场区隔：依国家

第十章：SWOT分析

  • 概述
  • 优势
  • 弱点
  • 机会
  • 威胁

第 11 章：价值链分析

第 12 章：波特五力分析

  • 概述
  • 买家的议价能力
  • 供应商的议价能力
  • 竞争程度
  • 新进入者的威胁
  • 替代品的威胁

第十三章：价格分析

第 14 章：竞争格局

  • 市场结构
  • 关键参与者
  • 关键参与者简介
    • Amgen Inc.
    • AstraZeneca plc
    • Daiichi Sankyo Company Limited
    • Merck & Co. Inc.
    • Novartis AG
    • Pfizer Inc.
    • Sanofi SA
Product Code: SR112025A5622

The global antihyperlipidemic drugs market size was valued at USD 13.1 Billion in 2024. Looking forward, IMARC Group estimates the market to reach USD 18.6 Billion by 2033, exhibiting a CAGR of 3.9% during 2025-2033. North America currently dominates the market, holding a significant market share of over 32.7% in 2024. The market in North America is fueled by the high prevalence of hyperlipidemia and cardiovascular diseases, aging populations, obesity, sedentary lifestyles, and unhealthy diets. Strong R&D investments, advanced healthcare infrastructure, government initiatives, rising adoption of statins, PCSK9 inhibitors, and novel lipid-lowering drugs, along with insurance coverage, further fuel antihyperlipidemic drugs market share.

Antihyperlipidemic drugs help lower serum levels of cholesterol and various lipids in the blood. They can be taken with different medications to control high cholesterol and reduce the risk of certain medical conditions. At present, their different classes are available worldwide, which can be given based on the patient's cholesterol profile, underlying disease, and other factors. Some of the commonly available antihyperlipidemic drugs include statins, antihyperlipidemic combinations, bile acid sequestrants, cholesterol absorption inhibitors, fibric acid derivatives, and PCSK9 inhibitors.

Antihyperlipidemic Drugs Market Trends:

The growing prevalence of hyperlipidemia on account of sedentary lifestyles, nicotine addiction, and high consumption of fatty foods represents one of the key factors catalyzing the demand for antihyperlipidemic drugs. Moreover, hyperlipidemia increases the risk of developing coronary artery disease (CAD), which is the most common cause of death among adults worldwide. As a result, there is a rise in the need for these drugs to reduce the high levels of low-density lipoprotein (LDL) cholesterol and triglycerides while increasing the low levels of high-density lipoprotein (HDL) cholesterol. Apart from this, they are used to treat children with high cholesterol levels and various lipid disorders. In addition, a surge in the number of genetic and acquired disorders of lipid and lipoprotein metabolism among the pediatric population is positively influencing the need for antihyperlipidemic drugs to reduce the rates of hospitalization and premature deaths. Furthermore, the approval of new and advanced drugs is creating a favorable outlook for the market. Besides this, medicinal chemists around the world are designing, synthesizing, and evaluating a variety of new molecules for these drugs, which is anticipated to contribute to the growth of the market.

Key Market Segmentation:

Breakup by Drug Class:

  • Statins
  • Bile Acid Sequestrants
  • Cholesterol Absorption Inhibitors
  • Fibric Acid Derivatives
  • PCSK9 Inhibitors
  • Combination
  • Others

Breakup by Route of Administration:

  • Oral
  • Intravenous

Breakup by Distribution Channel:

  • Hospital Pharmacies
  • Retail Stores
  • Online Retailers

Breakup by Region:

  • North America
  • United States
  • Canada
  • Asia-Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
  • Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
  • Latin America
  • Brazil
  • Mexico
  • Others
  • Middle East and Africa

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being Amgen Inc., AstraZeneca plc, Daiichi Sankyo Company Limited, Merck & Co. Inc., Novartis AG, Pfizer Inc. and Sanofi S.A.

Key Questions Answered in This Report

  • 1.How big is the antihyperlipidemic drugs market?
  • 2.What is the future outlook of the antihyperlipidemic drugs market?
  • 3.What are the key factors driving the antihyperlipidemic drugs market?
  • 4.Which region accounts for the largest antihyperlipidemic drugs market share?
  • 5.Which are the leading companies in the global antihyperlipidemic drugs market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Antihyperlipidemic Drugs Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Drug Class

  • 6.1 Statins
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Bile Acid Sequestrants
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Cholesterol Absorption Inhibitors
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Fibric Acid Derivatives
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast
  • 6.5 PCSK9 Inhibitors
    • 6.5.1 Market Trends
    • 6.5.2 Market Forecast
  • 6.6 Combination
    • 6.6.1 Market Trends
    • 6.6.2 Market Forecast
  • 6.7 Others
    • 6.7.1 Market Trends
    • 6.7.2 Market Forecast

7 Market Breakup by Route of Administration

  • 7.1 Oral
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Intravenous
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast

8 Market Breakup by Distribution Channel

  • 8.1 Hospital Pharmacies
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Retail Stores
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Online Retailers
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast

9 Market Breakup by Region

  • 9.1 North America
    • 9.1.1 United States
      • 9.1.1.1 Market Trends
      • 9.1.1.2 Market Forecast
    • 9.1.2 Canada
      • 9.1.2.1 Market Trends
      • 9.1.2.2 Market Forecast
  • 9.2 Asia-Pacific
    • 9.2.1 China
      • 9.2.1.1 Market Trends
      • 9.2.1.2 Market Forecast
    • 9.2.2 Japan
      • 9.2.2.1 Market Trends
      • 9.2.2.2 Market Forecast
    • 9.2.3 India
      • 9.2.3.1 Market Trends
      • 9.2.3.2 Market Forecast
    • 9.2.4 South Korea
      • 9.2.4.1 Market Trends
      • 9.2.4.2 Market Forecast
    • 9.2.5 Australia
      • 9.2.5.1 Market Trends
      • 9.2.5.2 Market Forecast
    • 9.2.6 Indonesia
      • 9.2.6.1 Market Trends
      • 9.2.6.2 Market Forecast
    • 9.2.7 Others
      • 9.2.7.1 Market Trends
      • 9.2.7.2 Market Forecast
  • 9.3 Europe
    • 9.3.1 Germany
      • 9.3.1.1 Market Trends
      • 9.3.1.2 Market Forecast
    • 9.3.2 France
      • 9.3.2.1 Market Trends
      • 9.3.2.2 Market Forecast
    • 9.3.3 United Kingdom
      • 9.3.3.1 Market Trends
      • 9.3.3.2 Market Forecast
    • 9.3.4 Italy
      • 9.3.4.1 Market Trends
      • 9.3.4.2 Market Forecast
    • 9.3.5 Spain
      • 9.3.5.1 Market Trends
      • 9.3.5.2 Market Forecast
    • 9.3.6 Russia
      • 9.3.6.1 Market Trends
      • 9.3.6.2 Market Forecast
    • 9.3.7 Others
      • 9.3.7.1 Market Trends
      • 9.3.7.2 Market Forecast
  • 9.4 Latin America
    • 9.4.1 Brazil
      • 9.4.1.1 Market Trends
      • 9.4.1.2 Market Forecast
    • 9.4.2 Mexico
      • 9.4.2.1 Market Trends
      • 9.4.2.2 Market Forecast
    • 9.4.3 Others
      • 9.4.3.1 Market Trends
      • 9.4.3.2 Market Forecast
  • 9.5 Middle East and Africa
    • 9.5.1 Market Trends
    • 9.5.2 Market Breakup by Country
    • 9.5.3 Market Forecast

10 SWOT Analysis

  • 10.1 Overview
  • 10.2 Strengths
  • 10.3 Weaknesses
  • 10.4 Opportunities
  • 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

  • 14.1 Market Structure
  • 14.2 Key Players
  • 14.3 Profiles of Key Players
    • 14.3.1 Amgen Inc.
      • 14.3.1.1 Company Overview
      • 14.3.1.2 Product Portfolio
      • 14.3.1.3 Financials
    • 14.3.2 AstraZeneca plc
      • 14.3.2.1 Company Overview
      • 14.3.2.2 Product Portfolio
      • 14.3.2.3 Financials
      • 14.3.2.4 SWOT Analysis
    • 14.3.3 Daiichi Sankyo Company Limited
      • 14.3.3.1 Company Overview
      • 14.3.3.2 Product Portfolio
      • 14.3.3.3 Financials
      • 14.3.3.4 SWOT Analysis
    • 14.3.4 Merck & Co. Inc.
      • 14.3.4.1 Company Overview
      • 14.3.4.2 Product Portfolio
      • 14.3.4.3 Financials
    • 14.3.5 Novartis AG
      • 14.3.5.1 Company Overview
      • 14.3.5.2 Product Portfolio
      • 14.3.5.3 Financials
      • 14.3.5.4 SWOT Analysis
    • 14.3.6 Pfizer Inc.
      • 14.3.6.1 Company Overview
      • 14.3.6.2 Product Portfolio
      • 14.3.6.3 Financials
    • 14.3.7 Sanofi S.A
      • 14.3.7.1 Company Overview
      • 14.3.7.2 Product Portfolio
      • 14.3.7.3 Financials

List of Figures

  • Figure 1: Global: Antihyperlipidemic Drugs Market: Major Drivers and Challenges
  • Figure 2: Global: Antihyperlipidemic Drugs Market: Sales Value (in Billion USD), 2019-2024
  • Figure 3: Global: Antihyperlipidemic Drugs Market Forecast: Sales Value (in Billion USD), 2025-2033
  • Figure 4: Global: Antihyperlipidemic Drugs Market: Breakup by Drug Class (in %), 2024
  • Figure 5: Global: Antihyperlipidemic Drugs Market: Breakup by Route of Administration (in %), 2024
  • Figure 6: Global: Antihyperlipidemic Drugs Market: Breakup by Distribution Channel (in %), 2024
  • Figure 7: Global: Antihyperlipidemic Drugs Market: Breakup by Region (in %), 2024
  • Figure 8: Global: Antihyperlipidemic Drugs (Statins) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 9: Global: Antihyperlipidemic Drugs (Statins) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 10: Global: Antihyperlipidemic Drugs (Bile Acid Sequestrants) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 11: Global: Antihyperlipidemic Drugs (Bile Acid Sequestrants) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 12: Global: Antihyperlipidemic Drugs (Cholesterol Absorption Inhibitors) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 13: Global: Antihyperlipidemic Drugs (Cholesterol Absorption Inhibitors) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 14: Global: Antihyperlipidemic Drugs (Fibric Acid Derivatives) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 15: Global: Antihyperlipidemic Drugs (Fibric Acid Derivatives) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 16: Global: Antihyperlipidemic Drugs (PCSK9 Inhibitors) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 17: Global: Antihyperlipidemic Drugs (PCSK9 Inhibitors) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 18: Global: Antihyperlipidemic Drugs (Combination) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 19: Global: Antihyperlipidemic Drugs (Combination) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 20: Global: Antihyperlipidemic Drugs (Other Drug Classes) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 21: Global: Antihyperlipidemic Drugs (Other Drug Classes) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 22: Global: Antihyperlipidemic Drugs (Oral) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 23: Global: Antihyperlipidemic Drugs (Oral) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 24: Global: Antihyperlipidemic Drugs (Intravenous) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 25: Global: Antihyperlipidemic Drugs (Intravenous) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 26: Global: Antihyperlipidemic Drugs (Hospital Pharmacies) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 27: Global: Antihyperlipidemic Drugs (Hospital Pharmacies) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 28: Global: Antihyperlipidemic Drugs (Retail Stores) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 29: Global: Antihyperlipidemic Drugs (Retail Stores) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 30: Global: Antihyperlipidemic Drugs (Online Retailers) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 31: Global: Antihyperlipidemic Drugs (Online Retailers) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 32: North America: Antihyperlipidemic Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 33: North America: Antihyperlipidemic Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 34: United States: Antihyperlipidemic Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 35: United States: Antihyperlipidemic Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 36: Canada: Antihyperlipidemic Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 37: Canada: Antihyperlipidemic Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 38: Asia-Pacific: Antihyperlipidemic Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 39: Asia-Pacific: Antihyperlipidemic Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 40: China: Antihyperlipidemic Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 41: China: Antihyperlipidemic Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 42: Japan: Antihyperlipidemic Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 43: Japan: Antihyperlipidemic Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 44: India: Antihyperlipidemic Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 45: India: Antihyperlipidemic Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 46: South Korea: Antihyperlipidemic Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 47: South Korea: Antihyperlipidemic Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 48: Australia: Antihyperlipidemic Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 49: Australia: Antihyperlipidemic Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 50: Indonesia: Antihyperlipidemic Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 51: Indonesia: Antihyperlipidemic Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 52: Others: Antihyperlipidemic Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 53: Others: Antihyperlipidemic Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 54: Europe: Antihyperlipidemic Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 55: Europe: Antihyperlipidemic Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 56: Germany: Antihyperlipidemic Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 57: Germany: Antihyperlipidemic Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 58: France: Antihyperlipidemic Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 59: France: Antihyperlipidemic Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 60: United Kingdom: Antihyperlipidemic Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 61: United Kingdom: Antihyperlipidemic Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 62: Italy: Antihyperlipidemic Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 63: Italy: Antihyperlipidemic Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 64: Spain: Antihyperlipidemic Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 65: Spain: Antihyperlipidemic Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 66: Russia: Antihyperlipidemic Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 67: Russia: Antihyperlipidemic Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 68: Others: Antihyperlipidemic Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 69: Others: Antihyperlipidemic Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 70: Latin America: Antihyperlipidemic Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 71: Latin America: Antihyperlipidemic Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 72: Brazil: Antihyperlipidemic Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 73: Brazil: Antihyperlipidemic Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 74: Mexico: Antihyperlipidemic Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 75: Mexico: Antihyperlipidemic Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 76: Others: Antihyperlipidemic Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 77: Others: Antihyperlipidemic Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 78: Middle East and Africa: Antihyperlipidemic Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 79: Middle East and Africa: Antihyperlipidemic Drugs Market: Breakup by Country (in %), 2024
  • Figure 80: Middle East and Africa: Antihyperlipidemic Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 81: Global: Antihyperlipidemic Drugs Industry: SWOT Analysis
  • Figure 82: Global: Antihyperlipidemic Drugs Industry: Value Chain Analysis
  • Figure 83: Global: Antihyperlipidemic Drugs Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Antihyperlipidemic Drugs Market: Key Industry Highlights, 2024 and 2033
  • Table 2: Global: Antihyperlipidemic Drugs Market Forecast: Breakup by Drug Class (in Million USD), 2025-2033
  • Table 3: Global: Antihyperlipidemic Drugs Market Forecast: Breakup by Route of Administration (in Million USD), 2025-2033
  • Table 4: Global: Antihyperlipidemic Drugs Market Forecast: Breakup by Distribution Channel (in Million USD), 2025-2033
  • Table 5: Global: Antihyperlipidemic Drugs Market Forecast: Breakup by Region (in Million USD), 2025-2033
  • Table 6: Global: Antihyperlipidemic Drugs Market: Competitive Structure
  • Table 7: Global: Antihyperlipidemic Drugs Market: Key Players